DSM broadens biocatalysis platform with c-LEcta enzymes
Heerlen/Leipzig – DSM Pharmaceutical Products, the custom manufacturing arm of Dutch Royal DSM NV, has licensed proprietary alcohol dehydrogenases from German enzyme specialist c-LEcta GmbH for enzyme screening programmes and development of sustainable manufacturing routes of pharmaceutical active ingredients and intermediates. c-LEcta, which has built up a unique collection of several hundred enzymes and enzyme mutants, will provide its alcohol dehydrogenases to be used for the cost-efficient synthesis of chiral secondary alcohols from ketones.
Additionally, DSM will apply c-LEcta’s InnoSyn route scouting to
identify more cost efficient routes for the development and manufacture of drug intermediates and ingredients by combining biocatalytic solutions with advanced chemical and process technologies. The new routes result in shorter cycle times due to fewer steps in the process with the same reliability and quality using more renewable starting materials.